This page shows you your search results in order of relevance. This is page number 14.
Order by Relevance | Date
Total 290035 results found since Jan 2013.
Spectrum and surgical outcomes of gastrointestinal stromal tumours
CONCLUSION: Whilst the numbers were small, certain trends were observed. Surgery in combination with imatinib offers survival benefit in patients undergoing R0, R1, R2, liver metastases and multivisceral resections.PMID:36477053 | DOI:10.17159/2078-5151/SAJS3721
Source: South African Journal of Surgery - December 8, 2022 Category: Surgery Authors: M S A Sithole F G Madela T N Buthelezi-Zulu T Lusu K Mody N E Nyakale V Pillay B P Hadebe F Anderson Source Type: research
A randomised phase 2 study of continuous or intermittent dosing schedule of imatinib re-challenge in patients with tyrosine kinase inhibitor-refractory gastrointestinal stromal tumours
British Journal of Cancer, Published online: 13 May 2023; doi:10.1038/s41416-023-02269-zA randomised phase 2 study of continuous or intermittent dosing schedule of imatinib re-challenge in patients with tyrosine kinase inhibitor-refractory gastrointestinal stromal tumours
Source: British Journal of Cancer - May 13, 2023 Category: Cancer & Oncology Authors: Hyung-Don Kim Changhoon Yoo Min-Hee Ryu Yoon-Koo Kang Source Type: research
Psychological and social challenges of patients with locally advanced and metastatic gastrointestinal stromal tumours (GIST) on long-term treatment with tyrosine kinase inhibitors: a qualitative study with patients and medical oncologists
ConclusionThe reported psychological and social challenges can significantly hamper the overall quality of life of GIST patients. Some challenges were clearly underreported and hardly recognized by medical oncologist, as they may tend to focus on the physical side effects and clinical outcomes of treatment. Therefore, it is essential to take the patient ’s perspective into account in research and clinical practice to ensure optimal care for this patient group.
Source: Supportive Care in Cancer - May 26, 2023 Category: Cancer & Oncology Source Type: research
Chinese consensus on management of tyrosine kinase inhibitor-associated side effects in gastrointestinal stromal tumors.
Abstract
Tyrosine kinase inhibitors (TKIs) have improved the overall survival of patients with gastrointestinal stromal tumors (GISTs), but their side effects can impact dose intensity and, consequently, the clinical benefit. To date, no guideline or consensus has been published on the TKI-associated adverse reactions. Therefore, the Chinese Society of Surgeons for Gastrointestinal Stromal Tumor of the Chinese Medical Doctor Association organized an expert panel discussion involving representatives from gastrointestinal surgery, medical oncology, cardiology, dermatology, nephrology, endocrinology, and ophthalmolog...
Source: World Journal of Gastroenterology - December 14, 2018 Category: Gastroenterology Authors: Li J, Wang M, Zhang B, Wu X, Lin TL, Liu XF, Zhou Y, Zhang XH, Xu H, Shen LJ, Zou J, Lu P, Zhang D, Gu WJ, Zhang MX, Pan J, Cao H, Chinese Society of Surgeons for Gastrointestinal Stromal Tumor of the Chinese Medical Doctor Association Tags: World J Gastroenterol Source Type: research
Extracellular domain c-kit mutation with duplication of Ser501Ala502 found in gastrointestinal stromal tumors is more imatinib- and nilotinib-sensitive than that with duplication of Ala502Tyr503
a
& Seiichi Hirota
Source: Laboratory Investigation AOP - March 4, 2013 Category: Laboratory Medicine Authors: Ning-Ning LiuMizuka OhkouchiYuka HashikuraNoriko KajimotoIkuo MatsudaKoji IsozakiYasushi TohTsuyoshi TakahashiToshirou NishidaSeiichi Hirota Tags: c-kit gene exon 9 gain-of-function mutation gastrointestinal stromal tumor imatinib nilotinib Source Type: research
Succinate dehydrogenase deficiency is associated with decreased 5-hydroxymethylcytosine production in gastrointestinal stromal tumors: implications for mechanisms of tumorigenesis
Jason L Hornick
Source: Modern Pathology AOP - June 7, 2013 Category: Pathology Authors: Emily F MasonJason L Hornick Tags: 5-hydroxymethylcytosine gastrointestinal stromal tumor KIT methylation PDGFRA succinate dehydrogenase TET Source Type: research
Frequent mono-allelic loss associated with deficient PTEN expression in imatinib-resistant gastrointestinal stromal tumors
& Maria Debiec-Rychter
Source: Modern Pathology AOP - April 18, 2014 Category: Pathology Authors: Anna QuattroneAgnieszka WozniakBarbara DewaeleGiuseppe FlorisVanessa VanspauwenThomas Van LooyPatrick SchöffskiPiotr RutkowskiRaf SciotMaria Debiec-Rychter Tags: gastrointestinal stromal tumor imatinib mesylate PTEN resistance Source Type: research
Good survival outcome of metastatic SDH-deficient gastrointestinal stromal tumors harboring SDHA mutations
erio Di Scioscio, Pietro Fusaroli, Anna Mandrioli, Lidia Gatto, Fausto Catena, Umberto Basso, Giorgio Ercolani, Antonio Daniele Pinna & Guido Biasco
Source: Genetics in Medicine - May 5, 2015 Category: Genetics & Stem Cells Authors: Maria A. PantaleoCristian LolliMargherita NanniniAnnalisa AstolfiValentina IndioMaristella SaponaraMilena UrbiniStefano La RovereAntony GillDavid GoldsteinClaudio CeccarelliDonatella SantiniGiulio RossiMichelangelo FiorentinoValerio Di ScioscioPietro Fusa Tags: gastrointestinal stromal tumors SDHA SDH deficient succinate dehydrogeanase wild-type Source Type: research
SLUG transcription factor: a pro-survival and prognostic factor in gastrointestinal stromal tumour
; Harri Sihto
Source: British Journal of Cancer - April 25, 2017 Category: Cancer & Oncology Authors: Olli-Pekka Pulkka Bengt Nilsson Maarit Sarlomo-Rikala Peter Reichardt Mikael Eriksson Kirsten Sundby Hall Eva Wardelmann Aki Vehtari Heikki Joensuu Harri Sihto Tags: gastrointestinal stromal tumour SLUG SNAI2 survival proliferation apoptosis Source Type: research
Ki-67 labeling index may be a promising indicator to identify “very high risk” gastrointestinal stromal tumor (GIST): a multicenter retrospective study of 1022 patients
We sought to determine whether Ki-67 labeling index (LI) was an independent prognostic factor for gastrointestinal stromal tumor (GIST). A multicenter cohort of 1022 patients undergoing surgical resection of primary GIST between August 2004 and October 2015 were retrospectively analyzed. Immunohistochemical analysis was performed to evaluate expression of Ki-67 in their parafin-embedded tissue samples. The optimal cutoff value of Ki-67 LI was determined as 6% by receiver operating characteristics (ROC) curve analysis.
Source: Human Pathology - September 26, 2017 Category: Pathology Authors: Xuechao Liu, Haibo Qiu, Peng Zhang, Xingyu Feng, Tao Chen, Yong Li, Kaixiong Tao, Guoxin Li, Xiaowei Sun, Zhiwei Zhou, On behalf of China Gastrointestinal Stromal Tumor Study Group (CN-GIST) Tags: Original contribution Source Type: research
Ki-67 labeling index may be a promising indicator to identify “very high-risk” gastrointestinal stromal tumor: a multicenter retrospective study of 1022 patients
We sought to determine whether Ki-67 labeling index (LI) was an independent prognostic factor for gastrointestinal stromal tumor (GIST). A multicenter cohort of 1022 patients undergoing surgical resection of primary GIST between August 2004 and October 2015 was retrospectively analyzed. Immunohistochemical analysis was performed to evaluate expression of Ki-67 in their paraffin-embedded tissue samples. The optimal cutoff value of Ki-67 LI was determined as 6% by receiver operating characteristics curve analysis.
Source: Human Pathology - September 26, 2017 Category: Pathology Authors: Xuechao Liu, Haibo Qiu, Peng Zhang, Xingyu Feng, Tao Chen, Yong Li, Kaixiong Tao, Guoxin Li, Xiaowei Sun, Zhiwei Zhou, China Gastrointestinal Stromal Tumor Study Group (CN-GIST) Tags: In this issue Source Type: research
